RESUMO
Regulatory compliance is challenging for multinational clinical trials. Conflicts between country requirements impedes research and slows the approval of medicines, leading the pharmaceutical industry to devote significant resources to this area. Many academic centers and nonprofits cannot support industry-level investment and are vulnerable to noncompliance. To address an insufficiency in public access to this information, the National Institute of Allergy and Infectious Diseases developed ClinRegs-a public access database of clinical research regulations. This report describes ClinRegs' features, maintenance, and usage. From September 2019 through August 2020, ClinRegs had 68 504 users, 60% from outside the United States, demonstrating the demand for accessible, reliable, country-specific regulatory information. Tools such as ClinRegs can help increase regulatory compliance and free up resources for research. We encourage our partner agencies and biomedical research industries to promote greater regulatory knowledge sharing and harmonization for the betterment of clinical research and improved public health.
Assuntos
Pesquisa Biomédica , Bases de Dados Factuais , Indústria Farmacêutica , Humanos , National Institute of Allergy and Infectious Diseases (U.S.) , Saúde Pública , Estados UnidosAssuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Vacinas contra COVID-19/efeitos adversos , Vacinas contra COVID-19/imunologia , COVID-19/imunologia , Anafilaxia/epidemiologia , Anafilaxia/etiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19/administração & dosagem , Centers for Disease Control and Prevention, U.S. , China , Indústria Farmacêutica , Seguimentos , Humanos , Imunização Secundária/efeitos adversos , Aplicativos Móveis , National Institute of Allergy and Infectious Diseases (U.S.) , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/efeitos adversos , Federação Russa , Autorrelato , Smartphone , Reino Unido , Estados UnidosAssuntos
COVID-19/epidemiologia , Ciência , Animais , Regiões Árticas , COVID-19/diagnóstico , COVID-19/prevenção & controle , COVID-19/virologia , Vacinas contra COVID-19/normas , Vacinas contra COVID-19/provisão & distribuição , China/epidemiologia , Dengue/prevenção & controle , Dengue/transmissão , Expedições , Saúde Global , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Indonésia/epidemiologia , Disseminação de Informação , Mosquitos Vetores/microbiologia , National Institute of Allergy and Infectious Diseases (U.S.)/organização & administração , Nova Zelândia/epidemiologia , Física , Política , Racismo/prevenção & controle , Segurança , Sexismo/prevenção & controle , Estados Unidos/epidemiologia , Uruguai/epidemiologia , Organização Mundial da Saúde/economia , Organização Mundial da Saúde/organização & administraçãoAssuntos
Monofosfato de Adenosina/análogos & derivados , Alanina/análogos & derivados , Antivirais/uso terapêutico , Betacoronavirus , Infecções por Coronavirus/tratamento farmacológico , Drogas em Investigação/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Monofosfato de Adenosina/efeitos adversos , Monofosfato de Adenosina/economia , Monofosfato de Adenosina/provisão & distribuição , Monofosfato de Adenosina/uso terapêutico , Alanina/efeitos adversos , Alanina/economia , Alanina/provisão & distribuição , Alanina/uso terapêutico , Antivirais/efeitos adversos , Antivirais/economia , Antivirais/provisão & distribuição , COVID-19 , Ensaios Clínicos Fase III como Assunto , Infecções por Coronavirus/epidemiologia , Aprovação de Drogas , Custos de Medicamentos , Drogas em Investigação/efeitos adversos , Drogas em Investigação/economia , Drogas em Investigação/provisão & distribuição , Doença pelo Vírus Ebola/tratamento farmacológico , Humanos , Tempo de Internação , National Institute of Allergy and Infectious Diseases (U.S.) , Pandemias , Pneumonia Viral/epidemiologia , Sistema de Registros , SARS-CoV-2 , Resultado do Tratamento , Estados Unidos/epidemiologia , Tratamento Farmacológico da COVID-19RESUMO
PURPOSE OF REVIEW: To present and discuss key design concepts for optimizing the impact of observational studies in the field of allergy and to highlight recent findings from NIAID-funded research networks. RECENT FINDINGS: We discuss three concepts. First, the benefit of prospective, longitudinal observational studies exemplified by recent findings on the seasonal nature of all rhinitis phenotypes in children with asthma and the protective effects of high house dust allergen content during the first year of life on the development of asthma at age 7 years. Second, the benefit of detailed (deep) phenotyping exemplified by the identification of a MALT1 gene variant as a strong genetic link to peanut allergy and the determination that atopic dermatitis with food allergy constitutes a distinct cutaneous endotype, compared with atopic dermatitis alone. Third, the benefit of hypothesis-generating research combined with prospective design and deep phenotyping as exemplified by the unveiling of potential pathophysiologic pathways leading to asthma exacerbations in children, after a 'cold'. SUMMARY: Observational studies can be highly impactful if designed well. Longitudinal study design, deep phenotyping, and hypothesis-generating research are three major design concepts that should be considered in the development of these studies.
Assuntos
Pesquisa Biomédica/normas , Hipersensibilidade/etiologia , Estudos Observacionais como Assunto/normas , Projetos de Pesquisa/normas , Alérgenos/imunologia , Pesquisa Biomédica/economia , Financiamento Governamental , Predisposição Genética para Doença , Humanos , Hipersensibilidade/diagnóstico , Estudos Longitudinais , Proteína de Translocação 1 do Linfoma de Tecido Linfoide Associado à Mucosa/genética , National Institute of Allergy and Infectious Diseases (U.S.)/economia , Estudos Observacionais como Assunto/economia , Estudos Prospectivos , Estados UnidosAssuntos
Erradicação de Doenças/legislação & jurisprudência , Governo Federal , Objetivos , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Política de Saúde/legislação & jurisprudência , Política , Centers for Disease Control and Prevention, U.S./economia , Centers for Disease Control and Prevention, U.S./organização & administração , Erradicação de Doenças/organização & administração , Erradicação de Doenças/tendências , Usuários de Drogas , Serviços de Planejamento Familiar/economia , Serviços de Planejamento Familiar/legislação & jurisprudência , Serviços de Planejamento Familiar/organização & administração , Infecções por HIV/economia , Infecções por HIV/transmissão , Política de Saúde/economia , Humanos , Masculino , National Institute of Allergy and Infectious Diseases (U.S.)/economia , National Institute of Allergy and Infectious Diseases (U.S.)/organização & administração , Estigma Social , Estados Unidos/epidemiologiaAssuntos
Pesquisa Biomédica , Epidemias/prevenção & controle , National Institute of Allergy and Infectious Diseases (U.S.) , Tuberculose/prevenção & controle , Controle de Doenças Transmissíveis , Humanos , Apoio à Pesquisa como Assunto , Tuberculose/diagnóstico , Tuberculose/epidemiologia , Vacinas contra a Tuberculose , Estados UnidosRESUMO
Survival of junior scientists in academic biomedical research is difficult in today's highly competitive funding climate. National Institute of Health (NIH) data on first-time R01 grantees indicate the rate at which early investigators drop out from a NIH-supported research career is most rapid 4 to 5 years from the first R01 award. The factors associated with a high risk of dropping out, and whether these factors impact all junior investigators equally, are unclear. We identified a cohort of 1,496 investigators who received their first R01-equivalent (R01-e) awards from the National Institute of Allergy and Infectious Diseases between 2003 and 2010, and studied all their subsequent NIH grant applications through 2016. Ultimately, 57% of the cohort were successful in obtaining new R01-e funding, despite highly competitive conditions. Among those investigators who failed to compete successfully for new funding (43%), the average time to dropping out was 5 years. Investigators who successfully obtained new grants showed remarkable within-person consistency across multiple grant submission behaviors, including submitting more applications per year, more renewal applications, and more applications to multiple NIH Institutes. Funded investigators appeared to have two advantages over their unfunded peers at the outset: they had better scores on their first R01-e grants and they demonstrated an early ability to write applications that would be scored, not triaged. The cohort rapidly segregated into two very different groups on the basis of PI consistency in the quality and frequency of applications submitted after their first R01-e award. Lastly, we identified a number of specific demographic factors, intitutional characteristics, and grant submission behaviors that were associated with successful outcomes, and assessed their predictive value and relative importance for the likelihood of obtaining additional NIH funding.
Assuntos
Pesquisa Biomédica , Financiamento de Capital , Financiamento Governamental , National Institute of Allergy and Infectious Diseases (U.S.) , Humanos , Estados UnidosRESUMO
Building on the success of the first Global Vaccine and Immunization Research Forum (GVIRF), the World Health Organization, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health in the United States of America, and the Bill & Melinda Gates Foundation convened the second GVIRF in March 2016. Leading scientists, vaccine developers, and public health officials from around the world discussed scientific advances and innovative technologies to design and deliver vaccines as well as novel tools and approaches to increase the uptake of vaccines throughout the world. This report summarizes the discussions and conclusions from the forum participants.
Assuntos
Saúde Global , Imunização , Vacinas , Fundações , Humanos , Imunização/métodos , National Institute of Allergy and Infectious Diseases (U.S.) , Saúde Pública , Pesquisa , Estados Unidos , Vacinação , Vacinas/administração & dosagem , Vacinas/imunologia , Organização Mundial da SaúdeRESUMO
: On 5-6 May 2016, the division of AIDS of the National Institute of Allergy and Infectious Diseases convened a workshop on 'HIV Birth Testing and Linkage to Care for HIV Infected Infants.' The goal of the workshop was to evaluate birth testing for early infant diagnosis (EID) of HIV, delineate technological resources for advancing a point-of-care (POC) HIV test implementable at birth and chart out the implementation hurdles for initiating early antiretroviral therapy to HIV-infected infants diagnosed at birth. The workshop addressed research and regulatory needs involved in the optimization of POC EID testing and challenges associated with implementation of EID, focusing on testing at birth. Scientific gaps and areas of intervention to accelerate and scale-up EID initiatives and birth testing were identified. These include discussion of the evidence supporting an early mortality peak among HIV-infected infant and justifying a role for birth HIV testing, including POC testing; evaluation of the current POC EID technology pipeline and test performance characteristics required for effective programmatic uptake; mathematical modeling of different testing scenarios and solutions with inclusion of birth testing; the adoption of setting-specific EID testing algorithms to achieve efficient linkage to care including early antiretroviral therapy initiation; the development of appropriate quality assurance programs to ensure accuracy of test results and enable sustainability of the testing program. Addressing these gaps and answering these challenges will be important in helping improve outcomes for HIV-infected infants and accelerate achieving the Joint United Nations Program for HIV and AIDS 90-90-90 targets in children.
Assuntos
Diagnóstico Precoce , Infecções por HIV/diagnóstico , Programas de Rastreamento/métodos , Cuidado Pós-Natal/métodos , Política de Saúde , Administração de Serviços de Saúde , Humanos , Lactente , Recém-Nascido , National Institute of Allergy and Infectious Diseases (U.S.) , Testes Imediatos , Nações Unidas , Estados UnidosRESUMO
Environmental exposures have been recognized as critical in the initiation and exacerbation of asthma, one of the most common chronic childhood diseases. The National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; and Merck Childhood Asthma Network sponsored a joint workshop to discuss the current state of science with respect to the indoor environment and its effects on the development and morbidity of childhood asthma. The workshop included US and international experts with backgrounds in allergy/allergens, immunology, asthma, environmental health, environmental exposures and pollutants, epidemiology, public health, and bioinformatics. Workshop participants provided new insights into the biologic properties of indoor exposures, indoor exposure assessment, and exposure reduction techniques. This informed a primary focus of the workshop: to critically review trials and research relevant to the prevention or control of asthma through environmental intervention. The participants identified important limitations and gaps in scientific methodologies and knowledge and proposed and prioritized areas for future research. The group reviewed socioeconomic and structural challenges to changing environmental exposure and offered recommendations for creative study design to overcome these challenges in trials to improve asthma management. The recommendations of this workshop can serve as guidance for future research in the study of the indoor environment and on environmental interventions as they pertain to the prevention and management of asthma and airway allergies.
Assuntos
Poluição do Ar em Ambientes Fechados/efeitos adversos , Asma/prevenção & controle , Indústria Farmacêutica , National Heart, Lung, and Blood Institute (U.S.) , National Institute of Allergy and Infectious Diseases (U.S.) , National Institute of Environmental Health Sciences (U.S.) , Organizações sem Fins Lucrativos , Animais , Asma/diagnóstico , Asma/epidemiologia , Pesquisa Biomédica , Criança , Conferências para Desenvolvimento de Consenso de NIH como Assunto , Saúde Ambiental , Obtenção de Fundos , Humanos , Estados UnidosRESUMO
Schistosomiasis remains a health burden in many parts of the world. The complex life cycle of Schistosoma parasites and the economic and societal conditions present in endemic areas make the prospect of eradication unlikely in the foreseeable future. Continued and vigorous research efforts must therefore be directed at this disease, particularly since only a single World Health Organization (WHO)-approved drug is available for treatment. The National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource Center (SRC) at the Biomedical Research Institute provides investigators with the critical raw materials needed to carry out this important research. The SRC makes available, free of charge (including international shipping costs), not only infected host organisms but also a wide array of molecular reagents derived from all life stages of each of the three main human schistosome parasites. As the field of schistosomiasis research rapidly advances, it is likely to become increasingly reliant on omics, transgenics, epigenetics, and microbiome-related research approaches. The SRC has and will continue to monitor and contribute to advances in the field in order to support these research efforts with an expanding array of molecular reagents. In addition to providing investigators with source materials, the SRC has expanded its educational mission by offering a molecular techniques training course and has recently organized an international schistosomiasis-focused meeting. This review provides an overview of the materials and services that are available at the SRC for schistosomiasis researchers, with a focus on updates that have occurred since the original overview in 2008.
Assuntos
Pesquisa Biomédica , National Institute of Allergy and Infectious Diseases (U.S.) , Schistosoma , Esquistossomose , Animais , Bancos de Espécimes Biológicos , Humanos , National Institute of Allergy and Infectious Diseases (U.S.)/estatística & dados numéricos , Estados Unidos , Organização Mundial da SaúdeAssuntos
Organização do Financiamento/legislação & jurisprudência , Organização do Financiamento/organização & administração , Pesquisadores , National Institute of Allergy and Infectious Diseases (U.S.) , Pesquisadores/economia , Pesquisadores/psicologia , Inquéritos e Questionários , Estados UnidosRESUMO
The World Health Organization, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Bill & Melinda Gates Foundation convened the first Global Vaccine and Immunization Research Forum (GVIRF) in March 2014. This first GVIRF aimed to track recent progress of the Global Vaccine Action Plan research and development agenda, identify opportunities and challenges, promote partnerships in vaccine research, and facilitate the inclusion of all stakeholders in vaccine research and development. Leading scientists, vaccine developers, and public health officials from around the world discussed scientific and technical challenges in vaccine development, research to improve the impact of immunization, and regulatory issues. This report summarizes the discussions and conclusions from the forum participants.
Assuntos
Pesquisa Biomédica/tendências , Vacinas , Vacinas contra a AIDS , Congressos como Assunto , Fundações , Saúde Global , Política de Saúde , Humanos , Imunização , Vacinas contra Influenza , Vacinas Antimaláricas , National Institute of Allergy and Infectious Diseases (U.S.) , Vacinas contra a Tuberculose , Estados Unidos , Organização Mundial da SaúdeAssuntos
Controle de Doenças Transmissíveis/métodos , Ebolavirus , Doença pelo Vírus Ebola/prevenção & controle , Parcerias Público-Privadas/economia , Antivirais/uso terapêutico , Controle de Doenças Transmissíveis/economia , Descoberta de Drogas , Vacinas contra Ebola/administração & dosagem , Doença pelo Vírus Ebola/tratamento farmacológico , Doença pelo Vírus Ebola/epidemiologia , Humanos , National Institute of Allergy and Infectious Diseases (U.S.) , Setor Privado/economia , Setor Público/economia , Estados Unidos , VacinaçãoRESUMO
Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.
Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/microbiologia , Pesquisa Biomédica/tendências , Financiamento de Capital , Farmacorresistência Bacteriana , Uso de Medicamentos/normas , Antibacterianos/farmacologia , Humanos , Liderança , National Institute of Allergy and Infectious Diseases (U.S.) , Estados UnidosRESUMO
The possibility of a public health radiological or nuclear emergency in the United States remains a concern. Media attention focused on lost radioactive sources and international nuclear threats, as well as the potential for accidents in nuclear power facilities (e.g., Windscale, Three Mile Island, Chernobyl, and Fukushima) highlight the need to address this critical national security issue. To date, no drugs have been licensed to mitigate/treat the acute and long-term radiation injuries that would result in the event of large-scale, radiation, or nuclear public health emergency. However, recent evaluation of several candidate radiation medical countermeasures (MCMs) has provided initial proof-of-concept of efficacy. The goal of the Radiation Nuclear Countermeasures Program (RNCP) of the National Institute of Allergy and Infectious Diseases (National Institutes of Health) is to help ensure the government stockpiling of safe and efficacious MCMs to treat radiation injuries, including, but not limited to, hematopoietic, gastrointestinal, pulmonary, cutaneous, renal, cardiovascular, and central nervous systems. In addition to supporting research in these areas, the RNCP continues to fund research and development of decorporation agents targeting internal radionuclide contamination, and biodosimetry platforms (e.g., biomarkers and devices) to assess the levels of an individual's radiation exposure, capabilities that would be critical in a mass casualty scenario. New areas of research within the program include a focus on special populations, especially pediatric and geriatric civilians, as well as combination studies, in which drugs are tested within the context of expected medical care management (e.g., antibiotics and growth factors). Moving forward, challenges facing the RNCP, as well as the entire radiation research field, include further advancement and qualification of animal models, dose conversion from animal models to humans, biomarker identification, and formulation development. This paper provides a review of recent work and collaborations supported by the RNCP.
Assuntos
Serviços Médicos de Emergência , National Institute of Allergy and Infectious Diseases (U.S.) , Desenvolvimento de Programas/economia , Estoque Estratégico , Animais , Serviços Médicos de Emergência/economia , Serviços Médicos de Emergência/métodos , Serviços Médicos de Emergência/organização & administração , Humanos , National Institute of Allergy and Infectious Diseases (U.S.)/economia , National Institute of Allergy and Infectious Diseases (U.S.)/organização & administração , Liberação Nociva de Radioativos , Projetos de Pesquisa , Apoio à Pesquisa como Assunto , Estoque Estratégico/economia , Estoque Estratégico/métodos , Estoque Estratégico/organização & administração , Terrorismo , Estados Unidos , Populações VulneráveisRESUMO
In November 2011, the National Institutes of Health convened a workshop of basic researchers, epidemiologists, and clinical experts in pelvic inflammatory disease to identify research gaps hindering advances in diagnosis, treatment, and prevention. This article summarizes the presentations, discussions, and conclusions of this group and highlights significant controversies that reveal aspects of pelvic inflammatory disease research that would most greatly benefit from the application of newer molecular, immunologic, and radiologic techniques. Multiple limitations to performing new clinical trials exist; however, emerging data from ongoing clinical trials will add to the current body of knowledge regarding prevention and treatment strategies. In addition, use of established health care databases could serve as a valuable tool for performance of unbiased epidemiologic outcome studies.